FABP-4
-0.015 ± 0.013 0.243 -1.308 ± 1.130 0.247 FABP-4 -fatty acid binding protein 4, HGF -hepatocyte growth factor, IL-1ra -interleukin-1 receptor antagonist, t-PA -tissue plasminogen activator*all 10 IR-risk SNPs were directly genotyped with the Illumina Cardio-MetaboChip array in PIVUS and ULSAM **β ± SE indicates the per-allele effect on normalized protein expression value of biomarker (SD-unit) ***β ± SE indicates the causal effect of one unit change in lnHOMA-IR on normalized protein expression value of biomarker (SD-unit) GWAS -genome wide association study, HGF -hepatocyte growth factor, IL-1ra -interleukin-1 receptor antagonist, NR -not reported, t-PA -tissue plasminogen activator, chr -chromosome, pos -position (Genome Reference Consortium Human Build 38), EA -effect-allele (biomarker-increasing allele), r2 -variance explained. ¶References: IL-1ra -PMID 24969107, HGF -PMID 25552591, t-PA -PMID 24578379. ¶ ¶proxy-SNP (r2 > 0.8) for rs55861089 (position 1783757, chromosome 11, effect/non-effect alleles A/g). *β ± SE indicates the per-allele effect on protein concentration (ln-tranformed for HGF and t-PA, log 2 -scaled normalized protein expression value for cathepsin D) **β ± SE indicates the per-allele effect on ln-transformed HOMA-IR***β ± SE indicates the causal effect of one unit change in biomarker (lntranformed for HGF and t-PA, SD-unit for cathepsin D) on lnHOMA-IR
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